Research programme: estrogen receptor alpha modulator therapeutics and diagnostics - Shenogen Pharma
Alternative Names: SNG 8003; SNG 8023; SNG-8006; SNG-8033; SNG-8038Latest Information Update: 28 Nov 2020
At a glance
- Originator Shenogen Pharma
- Class Diagnostic agents; Drug conjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action Estrogen receptor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Chronic myeloid leukaemia; Endometrial cancer; Lung cancer; Unspecified
- Discontinued Osteoporosis
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Breast-cancer in China
- 28 Nov 2020 No recent reports of development identified for preclinical development in Endometrial-cancer in China
- 28 Nov 2020 No recent reports of development identified for preclinical development in Unspecified(Diagnosis) in China